Skip to main content
Search
Search
About Angelman Syndrome
About FAST
For Researchers
Welcome
Apply for a Grant
Grant Application Process
FAST-Funded Research
For Pharma
Welcome
The Pharma-Research-Community Hub
FAST Ventures
Resources
For Families & Caregivers
Welcome
Newly Diagnosed?
Understanding AS Genetics and Genotypes
Treatment & Trials
Get Involved
Resources for Caregivers
For Donors & Investors
Welcome
Ways to Give
Cure Angelman Now (CAN)
FAST Ventures
Contact Us
Donate
Donate
Menu
Pharma
Angelman Syndrome News
Sort by category
Families & Caregivers
Research
Pharma
Donors & Investors
Latest
All
05/16/2024
Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome
04/15/2024
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
03/05/2024
MENA Angelman Symposium Q&A
02/29/2024
A Message from Lauren Black
01/03/2024
Ultragenyx Pharmaceutical Ultragenyx announces completion of enrollment in Global Phase 1/2 Trial of GTX-102
10/16/2023
Ultragenyx Pharmaceutical provides AS Development Pipeline Updates
